Press-release for stocks publishing date 2022 - 04

Prices are updated after-hours

publishing date : 2022 - 04 - 26 source : Www.biospace.com

save search

Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update
Published: 2022-04-26 (Crawled : 22:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M

Professional, Scientific, and T...

| 660.87% | O: 1.36% H: 16.59% C: -6.17%
biopharma

Arcus Biosciences to Report First Quarter 2022 Financial Results and Pipeline Update
Published: 2022-04-26 (Crawled : 22:00) - biospace.com/
RCUS 4 | $15.43 -0.45% 0.0% 520K

Health Technology

| -43.5% | O: -1.65% H: 0.15% C: -5.32%
arcus report results

ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Published: 2022-04-26 (Crawled : 22:00) - biospace.com/
EPIX | $6.25 -2.34% -0.31% 41K

Health Technology

| 5.93% | O: -0.51% H: 2.39% C: -4.26%
pharma conference

Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
Published: 2022-04-26 (Crawled : 22:00) - biospace.com/
AERI | $15.25 0.0%

Health Technology

| 90.85% | O: -1.63% H: 0.0% C: -3.95%
research

Castle Biosciences Completes Acquisition of AltheaDx
Published: 2022-04-26 (Crawled : 22:00) - biospace.com/
CSTL | $19.86 -1.0% -0.85% 110K

Health Technology

| -16.62% | O: -1.53% H: 0.0% C: 0.0%
acquisition bioscience

Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Published: 2022-04-26 (Crawled : 22:00) - biospace.com/
EXEL | $23.71 1.8% 1.73% 12

Health Technology

| 3.81% | O: -0.44% H: 0.44% C: -2.15%
results

Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
Published: 2022-04-26 (Crawled : 21:00) - biospace.com/
JSPR | $22.03 -0.36% -0.14% 45K

| 704.01% | O: -0.36% H: 2.2% C: 1.1%
jsp191 leukemia trial therapeutics order phase 1 acute myeloid leukemia

Agilent to Announce Second-Quarter Fiscal Year 2022 Financial Results May 24
Published: 2022-04-26 (Crawled : 18:00) - biospace.com/
A | $137.49 -1.23% 0.0% 5

Health Technology

| 13.21% | O: -0.49% H: 0.0% C: 0.0%
results

Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
Published: 2022-04-26 (Crawled : 18:00) - biospace.com/
PRPO 4 | $5.86 -4.72% -0.82% 7K

Health Technology

| 437.61% | O: 0.0% H: 15.6% C: -3.67%
hemescreen conference technology

Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma
Published: 2022-04-26 (Crawled : 18:00) - biospace.com/
PHIO | News | $0.671 -4.14% -4.17% 92K

Health Technology

| -41.23% | O: -4.39% H: 7.34% C: -4.59%
ph-762 treatment trial phase 2b

AMRA Medical's MRI-based body composition measurements used in Lilly's SURPASS-3 tirzepatide sub-study
Published: 2022-04-26 (Crawled : 17:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M

Health Technology

| 163.75% | O: 0.34% H: 1.41% C: -1.17%
tirzepatide

Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
Published: 2022-04-26 (Crawled : 14:20) - biospace.com/
CTXR | $0.7165 -6.62% -6.58% 810K

Health Technology

| -35.14% | O: -0.9% H: 3.64% C: -0.91%
treatment hemorrhoids enroll phase 2b

Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting
Published: 2022-04-26 (Crawled : 14:20) - biospace.com/
EVFM | $0.0149 16.41% -16.94% 0

Health Technology

| -94.81% | O: -1.25% H: 0.0% C: 0.0%
research health

Evolus to Report First Quarter 2022 Results and Provide Business Update
Published: 2022-04-26 (Crawled : 14:20) - biospace.com/
EOLS | $11.5 -1.71% -1.92% 2

Health Technology

| 1.05% | O: -0.7% H: 1.86% C: -1.5%
report results

Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
Published: 2022-04-26 (Crawled : 14:20) - biospace.com/
EVAX | $4.13 -0.24% -1.97% 0

Manufacturing

| 34.53% | O: 0.98% H: 0.0% C: -1.61%
PSNL | $1.3 -5.8% -6.15% 160K

Health Technology

| -78.93% | O: 0.81% H: 0.0% C: -7.56%
platform therapy

Abbott Recommends Rejection of Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
Published: 2022-04-26 (Crawled : 14:20) - biospace.com/
ABT | News | $106.89 -0.65% -0.09% 4.2M

Health Technology

| -10.42% | O: -0.6% H: 0.87% C: -1.38%
corporation

Rubius Therapeutics to Announce First Quarter 2022 Financial Results
Published: 2022-04-26 (Crawled : 14:00) - biospace.com/
RUBY | $0.057 -99.3% 760K

Health Technology